The recent ONO-4538-12 clinical study released at the ASCO-GI conference showed that compared with placebo, Nivolumab reduced the risk of death of patients by 37%, and the overall 12-month survival rate of patients treated with Ni..
The following is the stage analysis and conventional treatment plan for gastric cancer published on the American cancer website.TNM staging system for gastric cancerOne tool doctors use to describe cancer staging is the TNM syst..
Advanced gastric cancerGastric cancer has long been in the lead in terms of morbidity and mortality of malignant digestive tract tumors. The biggest reason is that once it is found to be in advanced stages, the prognosis is poor.�..
Although PD-1 immunotherapy has opened a new model of tumor treatment, and has a good performance in the treatment of non-small cell lung cancer (NSCLC), melanoma, bladder cancer and other cancers, the low efficiency is always PD ..
Gastric cancer patientsIntroduction: After clinical treatment of gastric cancer patients, in order to prevent recurrence and metastasis in the rehabilitation process, how can early detection of recurrence be done? What are the si..
Key points for diagnosis and treatment of tumors at the junction of gastroesophagus1 Gastroesophageal junction (GEJ) adenocarcinoma occurs at the junction of the esophagus and stomach.2 Accurate preoperative staging is the key to ..
Recently, the Global Oncologist Network reported that a patient with advanced cardia cancer liver metastasis has successfully survived for three years after treatment with a new technology in clinical trials. The patient is curren..
The 2016 NCCN Clinical Guidelines for Gastric Cancer updated the systemic treatment plan for metastatic or locally advanced gastric cancer in the first edition (NCCN.2016.V1).Among them, the DCF in the original first-line preferre..
The 2016 American Conference of Clinical Oncology (ASCO) is about to be held in Chicago as one of the most talked about academic conferences in the field of oncology. The new research and progress made by each ASCO conference are ..
According to the results of a large multicenter clinical trial led by scientists at the Dana Faber Cancer Research Center, after standard treatment fails, a targeted therapeutic drug can reduce the amount of blood flowing to the t..